## 3 Results  
### VO2 max and Lactate  
A one-way ANOVA (repeated measures analysis) within subjects for evaluating VO2 max and lactate before and after 4 weeks showed statistically significant results (VO2 max: F = 48.997, S = 0.000, \(p<0.05\); lactate: F = 3841.301, S = 0.000, \(p<0.05\)), 4 weeks after the interventions for both groups (Table 3). Also, statistically significant differences were observed for VO2 max and lactate between the two groups, 4 weeks after the interventions.  
A \(t\)-test for independent samples revealed statistically significant differences between the two groups for the variables of VO2 max and lactate, respectively (VO2 max: \(t=-6.04\), S (two-tailed) = 0.000, \(p<0.05\); lactate: \(t=4.33\), S (two-tailed) = 0.000, \(p<0.05\)), Table 4. The mean values of the VO2 max showed a statistically significant increase of 8 mL/kg/min for the first MI intervention group, compared to the second placebo group which showed an increase of 0.6 mL/kg/min, which means that VO2 max improved statistically significantly in the first MI intervention group. The mean values of the lactate in the first MI intervention group revealed statistically significant differences with a value of 6.7 mmol/L, compared to the second placebo group which showed a value of 7.7 mmol/L, which means that there was a statistically significant reduction in lactate in the first MI intervention group compared to the second placebo group.  
The partial variance effect size (\(\eta^{2}\)) for the VO2 max variable showed a large effect size (\(\eta^{2}\) = 0.46) and observed power = 1.00 (\(\alpha\) = 0.05). Also, the partial variance effect size (\(\eta^{2}\)) for the lactate variable showed a large effect size (\(\eta^{2}\) = 0.98) and observed power = 1.00 (\(\alpha\) = 0.05).  
\begin{table}
\begin{tabular}{c c c c c} \hline
**Demographic Characteristics** & \begin{tabular}{c} **Total Participants** \\ **n = 58** \\ \end{tabular} & \begin{tabular}{c} **First MI Group** \\ **n = 29** \\ \end{tabular} & \
\begin{tabular}{c} **Second Placebo** \\ **Group n = 29** \\ \end{tabular} &
\begin{tabular}{c} **Statistical Analysis** \\ \(p\) **Value** \\ \end{tabular} \\ \hline Dominant Leg & & Frequencies \% & Frequencies \% & Chi-square \\ \hline Right (n, \%) & 46 (79.3\%) & 25 (86.2\%) & 21 (72.4\%) & NS, \(p=0.19\)\({}^{\beta}\), \(p>0.05\) \\ \hline Left (n, \%) & 12 (20.7\%) & 4 (13.8\%) & 8 (27.6\%) & NS, \(p=0.19\)\({}^{\beta}\), \(p>0.05\) \\ \hline Grade II LAS—Leg & & & & \\ \hline Right (n, \%) & 39 (67.2\%) & 21 (72.4\%) & 18 (62.1\%) & NS, \(p=0.40\)\({}^{\beta}\), \(p>0.05\) \\ \hline Left (n, \%) & 19 (32.8\%) & 8 (27.6\%) & 11 (37.9\%) & \\ \hline Previous LAS—Leg & & & & \(t\)-test for Independent \\ \hline Right (n, \%) & 38 (65.5\%) & 17 (58.6\%) & 21 (72.4\%) & \\ \hline Left (n, \%) & 12 (20.7\%) & 6 (20.7\%) & 6 (20.7\%) & NS, \(p=0.30\)\({}^{\alpha}\), \(p>0.05\) \\ \hline Both (n, \%) & 8 (13.8\%) & 6 (20.7\%) & 2 (6.9\%) & \\ \hline Total number of previous LAS & & & Chi-square for Trends \\ \hline
1 (n, \%) & 30 (51.7\%) & 17 (58.6\%) & 13 (44.8\%) & \\ \hline
2 (n, \%) & 21 (36.2\%) & 9 (31.0\%) & 12 (41.4\%) & NS, \(p=0.35\)\({}^{\gamma}\), \(p>0.05\) \\ \hline \(\geq\)3 (n, \%) & 7 (12.1\%) & 3 (10.3\%) & 4 (13.8\%) & \\ \hline \end{tabular}  
NS = no significance, M = mean, SD = standard deviation; \({}^{\alpha}\)\(t\)-test, \(p<0.05\); \({}^{\beta}\)\(\chi^{2}\), \(p<0.05\); \({}^{\gamma}\)\(\chi^{2}\) for trends, \(p<0.05\).  
\end{table}
Table 2: _Cont._